Tovorafenib for high-grade glioma and DIPG
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a drug called tovorafenib for children and young adults with certain types of brain tumors that have specific genetic changes. It is aimed at helping people who have just finished radiation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 39 years old.
- You must have a high-grade glioma or DIPG with a MAPK pathway alteration.
- You must have been on the TarGeT-SCR study before.
- You must start treatment within 35 days after finishing radiation therapy.
- You need adequate organ function (bone marrow, kidney, liver, heart, thyroid).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This trial tests a combination of two immunotherapy drugs, relatlimab and nivolumab, for people with certain brain tumors (high-grade glioma or DIPG) that have DNA repair issues. The treatment aims to help the immune system fight the tumor.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Hear when a new High Grade Glioma (III or IV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.